General Investing >> Money Manager Interviews >> November 15, 2010
Les Funtleyder has been in the health care industry since 1993. He joined Miller Tabak + Co., LLC, in 2004 as a Health Care Strategist and Portfolio Manager of the Miller Tabak Health Care Transformation Fund. Before joining Miller Tabak, he managed a global long/short health care portfolio for Provident Advisors, a hedge fund in Minneapolis, Minn. Prior to Provident, Mr. Funtleyder worked as a medical device Analyst at UBS Warburg. Before going to UBS, he covered biotechnology stocks for Bigelow & Company, a health care research boutique in Denver, Colo. His industry experience includes directing clinical and business research at Innovative Health Solutions, a joint venture of Merck & Co., and Wyeth, which is now part of Pfizer, and as a Consultant to HMOs and hospitals for Coopers & Lybrand and Health Strategies Group. Mr. Funtleyder wrote Healthcare Investing: Profiting from the New World of Pharma, Biotech and Health Care Services, published in January 2009, which bridges the gap between health reform, innovation and investing. Mr. Funtleyder earned a B.A. from Tulane University and a Master of Public Heath (MPH) degree from Columbia University. Profile
TWST: You manage the Miller Tabak Health Care Transformation Fund. Give us some background on the fund.
Mr. Funtleyder: With the onset of health care reform, our sense was that there was going to be a
